Home > Boards > US OTC > Biotechs > Cytodyn Inc. (CYDY)

Actually it does, that’s why the operation Warp

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
Venture_Cap Member Profile
 
Followed By 71
Posts 7,918
Boards Moderated 1
Alias Born 09/28/12
160x600 placeholder
Additional Proxy Soliciting Materials (definitive) (defa14a) Edgar (US Regulatory) - 9/21/2021 9:31:07 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/21/2021 9:30:30 AM
CLS Holdings, (OTCQB: CLSH) FY 2021 $19 Million - 60% Growth - August Alone $1.8 million InvestorsHub NewsWire - 9/21/2021 7:09:12 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/20/2021 4:02:29 PM
Additional Proxy Soliciting Materials - Non-management (definitive) (dfan14a) Edgar (US Regulatory) - 9/20/2021 9:31:05 AM
Amended Statement of Beneficial Ownership (sc 13d/a) Edgar (US Regulatory) - 9/17/2021 5:24:23 PM
Additional Proxy Soliciting Materials (definitive) (defa14a) Edgar (US Regulatory) - 9/10/2021 4:05:53 PM
Additional Proxy Soliciting Materials - Non-management (definitive) (dfan14a) Edgar (US Regulatory) - 9/7/2021 1:49:04 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/3/2021 6:06:41 AM
Additional Proxy Soliciting Materials (definitive) (defa14a) Edgar (US Regulatory) - 9/3/2021 6:04:42 AM
Additional Proxy Soliciting Materials - Non-management (definitive) (dfan14a) Edgar (US Regulatory) - 9/2/2021 6:03:28 AM
Additional Proxy Soliciting Materials - Non-management (definitive) (dfan14a) Edgar (US Regulatory) - 8/31/2021 4:56:35 PM
Additional Proxy Soliciting Materials - Non-management (definitive) (dfan14a) Edgar (US Regulatory) - 8/31/2021 2:09:30 PM
CEO Presenting on the Emerging Growth Conference on September 1.  Register Now InvestorsHub NewsWire - 8/30/2021 7:00:00 AM
CEO Presenting on the Emerging Growth Conference on September 1.  Register Now InvestorsHub NewsWire - 8/30/2021 7:00:00 AM
Additional Proxy Soliciting Materials - Non-management (definitive) (dfan14a) Edgar (US Regulatory) - 8/26/2021 5:19:44 PM
Additional Proxy Soliciting Materials (definitive) (defa14a) Edgar (US Regulatory) - 8/25/2021 8:18:51 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/25/2021 8:11:48 AM
Additional Proxy Soliciting Materials - Non-management (definitive) (dfan14a) Edgar (US Regulatory) - 8/19/2021 4:49:51 PM
Additional Proxy Soliciting Materials (definitive) (defa14a) Edgar (US Regulatory) - 8/19/2021 8:13:24 AM
Additional Proxy Soliciting Materials - Non-management (definitive) (dfan14a) Edgar (US Regulatory) - 8/18/2021 5:17:11 PM
Proxy Statment - Contested Solicitations (definitive) (defc14a) Edgar (US Regulatory) - 8/18/2021 2:17:15 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/16/2021 5:27:55 PM
Proxy Soliciting Materials (revised) (prrn14a) Edgar (US Regulatory) - 8/13/2021 6:08:30 AM
Additional Proxy Soliciting Materials - Non-management (definitive) (dfan14a) Edgar (US Regulatory) - 8/13/2021 6:05:07 AM
Venture_Cap   Tuesday, 08/04/20 11:48:31 AM
Re: hopester post# 101962
Post # of 185305 
Actually it does, that’s why the operation Warp Speed was created. But it’s done their way under their protocols.

The FDA is pushing drug companies to expedite clinical trials in a professional manner and also allowing DSMB reviews mid way that would normally not be allowed. Pandemics typically push status quo.

FDA is responding to pressure no doubt.

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences